Dr. Alain C. Mita, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license M3028 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Hoag Memorial Hospital Presbyterian Newport Beach, CA
Medical groups
- Hoag Clinic (460 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 511
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 206 | 85 |
| Established patient office or other outpatient visit, 30-39 minutes | 193 | 56 |
| Telephone medical discussion with physician, 21-30 minutes | 43 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prochlorperazine Maleate Other prescribers in Newport Beach, CA | 38 |
| Ondansetron Hcl Other prescribers in Newport Beach, CA | 36 |
| Dexamethasone Other prescribers in Newport Beach, CA | 22 |
| Olanzapine Other prescribers in Newport Beach, CA | 19 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Newport Beach, CA | 16 |
| Omeprazole Other prescribers in Newport Beach, CA | 16 |
| Cabometyx (cabozantinib s-malate) | 14 |
| Prednisone Other prescribers in Newport Beach, CA | 12 |
| Mekinist (trametinib dimethyl sulfoxide) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 18 payments worth $4,832 in total to this clinician.
| Coherus Oncology, Inc. | $2,388 |
|---|---|
| Gilead Sciences, Inc. | $1,470 |
| Genzyme Corporation | $350 |
| Daiichi Sankyo Inc. | $247 |
| GlaxoSmithKline, LLC. | $120 |
| Merck Sharp & Dohme LLC | $65.69 |
| Amgen Inc. | $65.44 |
| Legend Biotech USA Inc. | $40.71 |
| Consulting Fee | $2,250 |
|---|---|
| Travel and Lodging | $1,278 |
| Food and Beverage | $889 |
| Compensation for services other than consulting (speaking, faculty) | $350 |
| Education | $65.44 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Coherus Oncology, Inc. Jun 1, 2025 | Consulting Fee LOQTORZI · Oncology | $2,250 |
| Gilead Sciences, Inc. Nov 5, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s description;4285091;VEM US;12258449 | $985 |
| Genzyme Corporation Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) CAPRELSA · Endocrine & Metabolic Diseases | $350 |
| Gilead Sciences, Inc. Nov 5, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s description;4285092;VEM US;12258449 | $293 |
| Amgen Inc. Sep 4, 2025 | Education in-kind | $32.72 |
| Amgen Inc. Jul 16, 2025 | Education in-kind | $32.72 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $245,148 in research payments for these studies, mostly to the institutions running them.
- BNT411-01
BioNTech SE - A Phase 1 Open-Label, Dose-escalated Trial of Tumor Necrosis Factor Alpha and Interleukin-2 coding Oncolytic Adenovirus TILT-123 in Combination with Pembrolizumab in Patients with Immune Checkpoint Inhibitor Refractor…
Merck Sharp & Dohme LLC - SRF114-101
Coherus Oncology, Inc. - BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Beone Medicines Ltd. · Recruiting · NCT06756932 - A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Beone Medicines Ltd. · Active, not recruiting · NCT06257264 - Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors
Taiho Oncology, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.